A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS3497 in Patients With MTAP Deficient Advanced Solid Tumors and Lymphomas
Latest Information Update: 20 May 2025
At a glance
- Drugs CTS 3497 (Primary)
- Indications Adenocarcinoma; Biliary cancer; Glioma; Lymphoma; Malignant-mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors CytosinLab Therapeutics
Most Recent Events
- 20 May 2025 New trial record